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Liver cancer is the ﬁfth most common cancer in men and the seventh in women. During the past 20 years, the incidence of HCC
has tripled while the 5-year survival rate has remained below 12%. The presence of circulating tumor cells (CTC) reﬂects the
aggressiveness nature of a tumor. Many attempts have been made to develop assays that reliably detect and enumerate the CTC
during the development of the HCC. In this case, the challenges are (1) there are few markers speciﬁc to the HCC (tumor cells
versus nontumor cells) and (2) they can be used to quantify the number of CTC in the bloodstream. Another technical challenge
consists of ﬁnding few CTC mixed with million leukocytes and billion erythrocytes. CTC detection and identiﬁcation can be used
to estimate prognosis and may serve as an early marker to assess antitumor activity of treatment. CTC can also be used to predict
progression-free survival and overall survival. CTC are an interesting source of biological information in order to understand
dissemination, drug resistance, and treatment-induced cell death. Our aim is to review and analyze the diﬀerent new methods
existing to detect, enumerate, and characterize the CTC in the peripheral circulation of patients with HCC.
1.Introduction
Hepatocellular carcinoma (HCC) is responsible for signiﬁ-
cant morbidity and mortality in cirrhosis and also accounts
for between 85% and 90% of primary liver cancer [1–3].
Most of HCCs in the world occur in the setting of cirrhosis
and over half-million of people develop liver cancer every
year and an almost equal number die of it [1, 2, 4].
The most important causes leading to HCC are the
HBV and HCV infections, heavy alcohol consumption,
aﬂatoxinB1,ageandgender(malesaremoresusceptiblethan
females), race (Asian and African over 20 years old), tobacco
consumption,obesityassociatedwithnonalcoholicfattyliver
disease,andtheincreaseoftheDiabetesIImellitus(thatrises
the risk factor between 2 and 3), genetic hemochromatosis,
primary biliary cirrhosis, and alpha1-antitrypsin deﬁciency
and autoimmune hepatitis [1, 2, 5–32].
Usually, HCC develops during a long process of inﬂam-
mation and ﬁbrosis, eventually leading to cirrhosis [2, 16, 33,
34].
HCC is one of the most aggressive cancers. Patients
who show progress over the terminal stage have 1-year
survival of less than 10%. The choice of the therapy and the
prognosis are dictated by the severity of the liver function,
portal hypertension, and medical comorbidities. National
and international consensus was established to choose the
best treatment adapted for each case and obtain the best
prognosis [1, 5–21, 24, 25, 27, 30, 35, 36].
In the ﬁeld of biology of tumors, some expressions have
been coined for the diﬀerent types of circulating cellular
elements. The term circulating tumor cells (CTC) deﬁnes
speciﬁcally the tumor cells detected in blood or lymphatic
vessels. Circulating cells in the bloodstream or in the
lymphatic system are considered to be tumoral microemboli
(CTM) and represent a collective migration. The terms
disseminated tumor cells (DTCs) and isolated tumor cell
(ITC) can be also found in the literature but are usually used
to deﬁne the cells that can be detected in both the organs and
the bloodstream. The word micrometastasis is usually used2 International Journal of Hepatology
to indicate tumor cells found in distant organs, the tumor
spread circulating of liver-derived cells [20, 37, 38].
The presence of CTC reﬂects the aggressiveness nature
of a solid tumor. Many attempts have been made to develop
assays that reliably detect and enumerate these cells. The
clinicalresultsobtainedwithsuchassayssuggestthatinsome
tumortypes,CTCdetectionandidentiﬁcationcanbeusedto
estimateprognosisandmayserveasanearlymarkertoassess
antitumor activity of treatment. In addition, CTC can be
usedtopredictprogression-freesurvivalandoverallsurvival.
CTC are an interesting source of biological information
in order to understand dissemination, drug resistance and
treatment-induced cell death [22, 23, 39–50].
In HCC animal models showed that 10 to 10 000 CTC
are capable to initiate new metastasis [20, 51–53]. Even
after curative resection, the tumor recurrence rate remains
high. Although CTC detection has been applied and well
documented in diﬀerent types of cancer, especially breast
cancer, CTC detection is not routinely performed in HCC
follow-up and remains in the experimental ﬁeld. However,
CTC detection might bring new interesting information of
metastatic process might be used as diagnostic tool of early
recurrence and may allow a better patient selection for liver
transplantation. Mechanisms of tumor recurrence are still
poorly understood. Several arguments point out that HCC
tumor cells can inﬁltrate the blood system as shown by the
presence of alpha-fetoprotein mRNA [54–64]. CTC seem to
be correlated with poor survival in many types of tumors
[54, 55, 57, 58, 62, 64].
However,HCCcirculatingcellsarestilldiﬃculttodetect,
and their presence and amount are poorly correlated with
eitherlong-termsurvivalorrecurrenceinthesettingofHCC.
Methods of CTC detection have to be highly sensitive
and speciﬁc. The ﬁrst technical challenge in this ﬁeld consists
of ﬁnding exceptional cells. Just a few CTC are mixed
with the approximately 10 million leukocytes and 5 billion
erythrocytes in 1mL of blood. To be useful, the method
used to identify circulating tumor cells must also detect all
tumor cells and discriminate them from nontumor cells.
[22, 37, 39, 40, 43, 47, 48, 65–67]. It is important ﬁrst to
have circulating hepatoma-speciﬁc biomarkers to be able to
detect the CTC and further to be useful to early diagnosis,
monitoringmetastasis,orposttreatmentrecurrencesofHCC
[68].
In this paper, we will ﬁrst focus on the speciﬁc markers
of HCC used to detect CTC, follow by the diﬀerent methods
of enrichment of CTC and ﬁnally we will describe the new
promising methods to study and detect the CTC from the
HCC.
2. HCCMarkersandTheirApplicationsforCTC
The hepatocellular carcinomas can synthesize various
tumor-related proteins, polypeptides, and isoenzymes more
or less speciﬁc of the hepatoma tissues as well as the
corresponding mRNA. Itis important tohave tumor-speciﬁc
markers of HCC to detect CTC in the bloodstream or
lymphatic system.
2.1. Relevance of Cytokines in HCC Circulating Tumor Cells.
HCC tumor has shown to secret a lot of cytokines related
to the development of the tumor, like vascular endothelial
growth factor (VEGF), transforming growth factor-beta 1
(TGF-β1), Interleukin 8 (IL-8), or tumor-speciﬁc growth
factor (TSGF). These serum markers are useful to follow-up
the development and the prognosis of the HCC but useless
to follow-up circulating tumor cells in blood [69]. Because
of that the detection of the cytokine(s) and the mRNA
marker(s) simultaneously increases the speciﬁcity and the
sensitivity the methods of detecting CTC.
2.2. α-Fetoprotein (AFP). The serum α-fetoprotein (AFP)
levels show high levels in newborns and then decline
progressively below 10ng/mL in 300 days of life. An increase
of serum AFP levels can be observed during pregnancy,
and in patients with mucoviscidosis, acute hepatitis (30%–
50%), chronic hepatitis (15%–50%), cirrhosis (11%–47%)
and other cancers (gastrointestinal, pancreatic, biliary, non-
seminomatous germ-cell testicular, and germ cell ovarian).
Serum level AFP sensitivity is between 39% to 64% with
approximately 60% for a cutoﬀ of 20ng/mL and decrease to
22% if higher cutoﬀ of 200ng/mL is used [9, 70–74]. AFP
speciﬁcity is around 76%–91% with a low predictive value
between 9%–32% [9, 70–72].
In addition, the serum AFP level is correlated with the
tumor size. 80% of small HCC (<2cm) do not express
AFP. In the other hand, AFP level can be elevated in
patients with chronic liver disease with high degree of
hepatocytes regeneration such as HCV-infection that show
a high level of AFP in absence of malignancy [75, 76]. For
these reasons, some additional serological markers used in
combination with AFP seem to improve the performance of
this biomarker alone, especially in term of sensitivity.
Studies were done by using one or two more markers like
des-γ carboxyprothrombin (DCP) also called prothrombin
induced by vitamin K absence II (PIVKAII) and glycosylated
AFP-L3 (Lens culinaris Agglutinin-Reactive AFP) fraction
serum levels to diagnose earlier HCC and increasing the
sensitivity especially when HCC is associate with cirrhosis,
HCV or HBV infection [71, 74, 77–81]. But there is no study
that correlates their serum levels and the circulating tumor
cell during the HCC development.
BecauseofthatserumAFPandmRNAAFPdetectioncan
be used.
T h er e l e v a n c eo fA F Pm R N Aa sam a r k e ro fc i r c u l a t i n g
tumor cells is better but is also controversial because these
cells have not been further characterized, and it has been
shown that they may correspond to normal circulating
hepatocytes [58, 82, 83]. Furthermore, these tumor cells
have mostly been sought and detected shortly after liver
resection [56, 58, 62, 82, 83]. This ﬁnding suggests that CTC
could spread following liver mobilization or manipulation.
Although the mechanisms leading to intra, and extrahepatic
recurrences are still unknown, some observations suggest
that bone marrow (BM) could also be a speciﬁc reservoir of
CTC. Indeed, several reports have suggested that tumor cells
are from BM origin [84–86]. Hepatic tumor stem cells mayInternational Journal of Hepatology 3
Table 1:Evaluationofserumalphafetoproteinasamarkerofcirculationtumorcellindiﬀerenthepatocellularcarcinomastudies.nRT-PCR,
nested RT-PCR; qRT-PCR, quantitative RT-PCR.
Author PCR Sensitivity Cases Samples Positivity Predictability of recurrence
[55]q R T - P C R 1 C H C / 1 0 7 37
136
Blood
BM
18%
28%
No
Yes
[64]q R T - P C R 1 C H C / 1 0 6 38
25
Blood
BM
10%
48%
Yes
No
[56]n R T - P C R 5 c e l l s / 1 m L 2 4 Blood
BM
29%
43% Suspect
[54] Competitive RT 10 cells/9mL 22
11
Blood
BM
26%
45% NA
[90] RT-PCR NA 18 BM 93% No
[61, 62] nRT-PCR 33 Blood 52% Extrahepatic metastases
[57] nRT-PCR 15 cells/mL 64 Blood 36% Extrahepatic metastases
[58]n R T - P C R 1 C H C / 1 0 5 mono 20 Blood 25% No
[91]n R T - P C R 1 0 −6 μg/μL of RNA 33 Blood 54% Yes
[92]n R T - P C R 1 C H C / 1 0 5 mono 87 Blood 36% Yes
[93]n R T - P C R 1 C H C / 1 0 7 mono 85 Blood 26–45% No
[88] RT-PCR 1 CHC/106 52 Blood 25% No
take advantage of the potential for stem cell support of the
BM microenvironment. The ampliﬁcation of AFP mRNA by
means of reverse transcription (RT) and a nested polymerase
chain reaction (PCR) is the highly sensitive method for
the detection of residual HCC cells in peripheral blood.
The qualitative (positive versus negative) detection of HCC
circulating tumor cells in blood samples from individual
patients is of limited value in predicting the risk of disease
progression. Because the level of AFP mRNA is increased
in HCC tissue compared with in normal hepatocytes, the
quantiﬁcation of AFP transcripts seems to be a more reliable
indicator of disease progression. A more highly sensitive
assay based on TaqMan technology to quantify AFP mRNA
in “real time” should be preferred [59, 87–89]. Even using
thismethodology,reportedresultsarenothomogeneousand
contradictory [72]. The main studies which have evaluated
AFP mRNA are summarized in Table 1. The false-positive
results can be obtained using AFP mRNA.
2.3. Alpha Albumin (ALF). For more than a decade, we
know that mRNAs of hepatocytes-speciﬁc albumin genes are
detected in peripheral blood by RT-PCR. It was shown that
there is evidence that detection of albumin mRNA associated
with the detection of AFP mRNA is strongly associated with
the presence of metastases [57, 61, 94, 95]. Wong et al.,
showed that circulating hepatocellular carcinoma cells can
be detected and be semiquantiﬁed by albumin RT-PCR [96].
On the other hand, Resto et al., showed that downregulation
of alpha-albumin (ALF) speciﬁcally in HCC-circulating cells
can be used as a speciﬁc marker to discriminate the normal
hepatocellular circulating cells that express abundantly ALF.
RT-PCR ALF in association with RT-PCR AFP have been
proposed to distinguish normal or malignant hepatocytes in
peripheral blood, but the interpretation of the results is still
debated [97].
2.4.TransformingGrowthFactorBeta-1(TGF-β1). Thelevels
of circulating TGF-β1a n dT G F - β1 mRNA were signiﬁcantly
higher in the HCC patients than any other group of
patients. The sensitivity and speciﬁcity of circulating TGF-
β1l e v e l( >1.2μg/L) were 90% and 94% for HCC diagnosis,
but no signiﬁcant correlation was found between TGF-
β1 expression an AFP levels or tumor size. The combined
detectionofTGF-β1andserumAFPcouldraisethedetection
rateofHCCupto97%.BothofcirculatingT GF-β1andT GF-
β1mRNAcouldbeusedassensitivebiomarkersfordiagnosis
andprognosisofHBV-inducedHCC[98,99].Unfortunately,
TGF-β1mRNAwaspoorlystudiedandfurtherinvestigations
havetobedonetousecirculatingTGF-β1mRN Aasamark er
of circulating tumor cells in HCC.
2.5. Insulin-Like Growth Factor (IGF)-II. Studies using
ampliﬁed fragments of IGF-II mRNA by RT-PCR showed
that the lowest sensitivity with 2ng/L of total RNA. Dong
et al., showed that the positive frequencies of IGF-II mRNA
were100%inHCC,around50%inparacancerousand0%in
noncanceroustissuesrespectively.But,thepositivefrequency
of circulating IGF-II mRNA was 34% in HCC, and no
ampliﬁcation was found in other liver diseases, extrahepatic
tumors, and normal control, meaning that IGF-II is speciﬁc
of the HCC but not really sensitive. Associated to other
circulating markers IGF-II can be helpful to detect CTC. The
circulating IGF-II mRNA was correlated with the stage of
HCC (incidence = 100%) with extrahepatic metastasis and
35% with AFP-negative. No diﬀerence was found between
tumor size and circulating IGF-II mRNA [99, 100] but these
results are controversial [101].
2.6. Prostate-Speciﬁc Antigen (PSA). The Prostate-Speciﬁc
Antigen (PSA) had shown to be well-established reliability
marker and remained a valid prostate marker in patients4 International Journal of Hepatology
with acute hepatitis and HCC [102]. But these results are
controversial,PSAandmRNAPSAseemtodonotbespeciﬁc
to the tissue and frequently detected in peripheral blood cells
from healthy patients [17]. In addition, like the cytokines,
serum PSA cannot be used as hepatocellular carcinoma
marker for circulating tumor cells.
2.7. Heat Shock Protein (HSP). Heat shock proteins (HSPs)
are stimulated under perturbation or stressors by the tissue.
HSPs are ubiquitous molecules and can be also expressed
during carcinogenesis. Diﬀerent HSPs have been related to
the development of the hepatocellular carcinoma like gp96
or GRP94, HSP70 and HSP27, but none of them were used
as a speciﬁc marker of circulating tumor cell [99].
2.8. Human Telomerase Reverse Transcriptase (hTERT).
Human telomerase is a ribonucleic protein composed by the
associationofthreestructures:humantelomeraseRNAcom-
ponent (hTERC); human telomerase-associated protein 1
(hTEP1); human telomerase reverse transcriptase (hTERT).
hTERT is the catalytic unit of the complex. Also, telomerase
is expressed in embryonic cells, in most human cancer
cells or immortal cell lines, but not in normal somatic cell
lines or tissues. For these reasons hTERT was investigated
as a marker of diagnosis and prognosis of HCC, but the
results are controversial and appear that false-positive results
can be observed because of lymphocytes, precancerous liver
parenchymal cells, and micrometastasis maybe responsible
(for review [69, 99, 103]). Recently, Kong et al. investigated
hTERT in peripheral blood in HCC from 343 Korean
patients. There is no association between hTERT expression
and clinical features and not a relationship between AFP and
hTERT mRNA. Their conclusion is that AFP and hTERT
mRNA expression in peripheral blood is useless as HCC
prognostic markers [104].
2.9. Cancer-Testis Antigens (CTA). Cancer-testis antigens
(CTAs) represent a category of tumor-associated antigens
normally expressed in male germ cells but not in adult
somatic tissues [105]. CTAs are heterogeneous group of anti-
gens. Actually, more than 44 distinct CT “gene” or “antigen”
families have been reported in literature. Certain CT gene
families contain multiple members, as well as splice variants
and today more than 89 distinct transcripts are known to be
encoded by CT genes [105]. A number of CT antigens have
been found expressed with high percentage and speciﬁcity
in HCC. The expression of the CT antigens mRNA was
investigated by Wu et al., in HCC and corresponding
peripheral blood of 37 patients with HCC, 15 samples
of cirrhotic tissues and 15 normal tissues with the same
method. Two CT antigens SSX-2 and SSX-5 showed in this
studyhighspeciﬁcandhighfrequentexpressiononlyinHCC
tissues. In corresponding peripheral blood of HCC tissues,
the positive expressions rate of these two CT antigens mRNA
was not very high [106]. The same group of researchers
used another two CT antigens SSX-1 and NY-ESO1 in
the same group of patients and with the same methods
(RT-PCR) with the corresponding peripheral blood. They
showedthatSSX-1canbepotential usedinperipheralblood,
with short-term recurrence rate at 46% (6/13) in patients
whose peripheral blood expressed SSX-1 mRNA, while the
recurrence rate in patients with negative SSX-1 mRNA was
28.6% (4/14) [107]. In another study, Peng et al., showed
that speciﬁc expression of CT antigens was observed in AFP-
negative HCC, suggesting the application of their mRNA
as tumor markers to detect circulating HCC cells [108].
Yang et al., showed that FATE/BJ-HCC-2 (another CTA)
mRNA expression was detected in the peripheral blood
mononuclear cells (PBMCs) of 46.67% patients, whose HCC
tissue samples were cut oﬀ and positive for FATE/BJ-HCC-2
mRNA, which implicated tumor cell dissemination in blood
circulation and related to the metastasis of HCC. These
studies suggest that CT antigens expressions can be used in
peripheral blood to detect HCC circulating cells but also can
be associated to the research of AFP mRNA to increases the
speciﬁcity and the frequency of the method. This group of
markersseemspromisingandfurtherstudieshavetobedone
ﬁrst to determine the panel of CT antigens to be used as
markers of HCC circulating cells.
3. New Approachesto DiscoverNew Markers
To attempt the lack of CTC markers, new techniques
and technologies are used such as microarray/mRNA large
analyses, proteomic and “secretome” analyses and ﬁnally
microRNA testing.
3.1. Microarray/mRNA LargeAnalyses. DNA chips wereused
to measure and ﬁnd new markers to diagnose HCC but
also to use these as CTC markers. The studies showed the
expression of mRNAs for members of the glypican and
syndecan families of heparin sulfate proteoglycans such as
GPC3. GPC3 can be a good CTC marker that can be used
in human or mouse models [109, 110]. Another interesting
marker was discovered called Snail. Snail mRNA was studied
in blood of patients with HCC and metastasis [80]. But
further investigation has to be done to ﬁgure out the
speciﬁcity and the sensitivity of those markers.
3.2. Proteomic and Secretome Analyzes. In the process to ﬁnd
new markers for CTC, a number of teams started to work
with proteomic analysis such as quadrupole IT-TOF, SELDI-
TOF MALDI-TOF/TOF mass spectrometry. Their objective
is tracking earlier the development and the progression of
the HCC. Few markers or group of markers were identiﬁed
by these methods such as the usual markers AFP, AFP-
L3, TGF-β1, and PIVKA-II but also vitronectin, alpha-
1-fucosidase (AFU) and DCP, Golgi protein-73 (GP73),
hepatocyte growth factor (HGF), and nervous growth factor
(NGF) [111–117].
Interestingly, the proteomic analyses were able to detect
new markers in the serum secreted (which is called “secre-
tome”) by the carcinoma cells. [118–120]. Over 90 proteins
in some studies compiled with high powerful biocomputa-
tional analysis where identiﬁed and used to diagnose HCC
early [111, 113, 115, 116]. Unfortunately these studies didInternational Journal of Hepatology 5
not analyze the real usefulness of these markers to identify
CTC in the patients with HCC.
A subgroup of HCC was identiﬁed by these techniques
expressingstemcellmarkers(CD133,CD90,CD44,EpCAM,
CD13 or neural cell adhesion molecule; NCAM) deﬁning
what is called now liver cancer stem cell, but unfortunately
these markers were not study in the area of circulating
tumor cells [121–123], but they are very promising markers.
Another group of markers very promising to detect CTC
belongtothechemokinereceptorssuchasCXCR4,CX3CR1,
and CCR6 express during HCC progression [123, 124], but
none of them were tested during a clinical trial.
3.3. MicroRNA Markers: A New Hope. Around 28 years
ago, microRNA (miRNA) was discovered and showed the
regulation of genes [125, 126]s u c ha so n c o g e n e so rt u m o r
suppressor genes at the level of the mRNA. More than 35
studies focused on the identiﬁcation of miRNA or a group of
miRNAstobeusedasmarkerofearlydiagnosisormetastasis.
miR-122/-122a, miR-221/222, miR-145, miR-146a, miR-26
(NFκB pathway), miR-199a-3p (mTOR pathway), and miR-
26 (MYC pathway) were strongly linked to the development
and metastasis of the HCC and also a group of miRNAs were
used to identify and classify HCC [127–132], but none of
them were used as a CTC marker and tested during a clinical
trial.
3.4. Cancer Stem Cell (CSC) Marker in HCC Associated
with Flow Cytometry. Fan et al. described a multicolor ﬂow
cytometry used to detect the number of circulating CSCs
(CD45− CD90+ CD44+) in the peripheral circulation HCC
patients. Circulating CSCs predicted posthepatectomy HCC
recurrence with high accuracy. They may be the target
of eradication in the prevention of posthepatectomy HCC
metastasis, recurrence and also will be used to monitor
the eﬃciency of postsurgery treatment of the HCC [133].
The major problem of this technique beside the cost of the
equipment is the fact that it detects only a part (cancer stem
cells) and not the whole CTC decreasing the sensitivity of the
method and increasing false-negative results.
4. Conclusion
In conclusion, we can observe that not too many speciﬁc
HCC markers are available and useful for the detection of
the CTC. This is certainly due to the heterogeneity of the
hepatocellular carcinoma. The most important marker used
in clinical routine is the detection of serum AFP mRNA
expression (Table 1). But this marker is not expressed in all
HCC and by consequence in all CTC leading false-negative
results. Some propose to combine the research of more than
one marker to increase the speciﬁcity and the sensitivity of
CTC detection method. One of promising marker is Cancer-
Testis Antigens, but more studies need to be done to select
one or more CTA combined (or not) with the detection of
the AFP mRNA expression. As we notice previously, CTC
are very rare in peripheral blood. We saw also that real-time
polymerase chain reaction is a method that in addition to
be speciﬁc by the nature of the primers used it can amplify
the signal by increasing the number of copies of mRNA
originally presents in the sample.
Interestingly,theMilanCriteriaandModelforEnd-Stage
Liver Disease (MELD) system for the allocation of livers in
the United States do not include CTC markers to select the
recipient [134]. Among all of these CTC markers described
above, only AFP is routinely available before transplant.
Although its performance as a screening test is unsatisfactory
[135], but it is a valuable predictor of HCC recurrence and
patients survival after transplant [136, 137]. In Korea, a
scoring system incorporating tumor size, number, and AFP
has been proposed for the selection of transplant candidates
[138].ThesedatasuggestthatserumAFPcouldbeintegrated
with the Milan Criteria and the MELD system’s HCC to
improve selection criteria for prioritization patients on the
waiting list. Following this idea, it will be interesting to
assess the consequences of including more than one CTC
markers in the scoring system to select HCC patients for liver
transplantation and their followup.
But before using these markers, it is necessary to
concentrate the number of CTC from the peripheral blood
in a smaller volume. The next paragraph will describe these
methods.
5. Enrichment of the Sample
CTC are usually detected in the peripheral circulation, but
we can ﬁnd CTC in other body ﬂuids like the cerebrospinal
ﬂuids or the urines. The limitations to discover the CTC
in these ﬂuids are the same than in the blood circulation.
However, it is possible to extract a relatively big amount of
blood without harming the patient and much easier.
We will focus on the methods of CTC detection in
the blood. As we describe above, CTC in the peripheral
circulation occur at an estimated number of one CTC per
105−7 peripheral blood mononuclear cell or PBMC. Because
of the scarcity of the target cells, it is necessary to concentrate
thesample.Sinceenrichment willinevitablybeaccompanied
by some loss of CTC, irrespective of the method, some essays
are performed directly in whole blood [89].
Two diﬀerent groups of techniques can be used to
enrich samples, the nonspeciﬁc and the speciﬁc enrichment
techniques. The nonspeciﬁc enrichment techniques use
physicochemical CTC properties (size, density, etc.). The
speciﬁc enrichment technique uses markers expressed by the
CTC. Advantages of the nonspeciﬁc and speciﬁc enrichment
techniques are summarized in the Table 2 and described in
the following paragraphs.
6. The Nonspeciﬁc EnrichmentTechniques
6.1. Density Gradient(s) Centrifugation. The tumor cells,
epithelial cells, platelets, and low-density leukocytes from
leukocytes and erythrocytes can be separated by the propri-
etyoftheirparticulardensity(Table 2).Densitygradientcen-
trifugationisthepreferredmethodtopurifycells,subcellular
organelles, and macromolecules. Density gradients can be6 International Journal of Hepatology
Table 2: Summary of advantages and disadvantages of the methods of CTC enrichment. CTC, circulating tumor cell; CTC-Chip, circulating
tumor cell chip; EPIPSPOT, epithelial immunospot; FACS, ﬂuorescence-activated cell sorting = ﬂ o wc y t o m e t r i c ;F A S T ,ﬁ b e r - o p t i ca r r a y
scanning technology; ICH, immunocytochemistry; ISET, isolation by size of epithelial tumor cells; MACS, magnetic cell sorting; MEMS,
microelectromechanical system.
Methods of enrichment Advantages Disadvantages References
Nonspeciﬁc
Density
(OncoQuick, Ficoll, UNI-Set)
(1) Isolation of whole and living CTC,
(2) using another method of enrichment
more speciﬁc (immunomagnetic beads),
(3) cytopathology, cytological staining, ICH,
FISH, and so forth can be performed
(4) RNA, DNA extractions followed by
RT-PCR or PCR, respectively, can be done.
(1) Nonspeciﬁc,
( 2 )r a r eC T Cc a nb el o s ti nt h e
plasma fraction or trapped among
erythrocytes and neutrophils,
(3) low and variable sensitivity,
(4) Depends on the type of CTC,
temperature, and centrifuge,
(5) expensive.
[47, 65, 139, 140]
Size
(MEMS, ISET)
(1) Easy,
(2) precise counting of the cells per mL of
blood, independently of the volume of the
blood treated,
(3) Allowing cytopathology, cytological
staining, ICH, FISH, and so forth,
(4) Allowing Microdissection followed by
(5) RNA, DNA extraction followed by
RT-PCR or PCR respectively
(6) Avoiding multiple steps,
(7) Increasing sensitivity (1 single CTC can
be detect from 1mL of blood).
(1) Nonspeciﬁc,
(2) CTC can go through the ﬁlter,
(3) cells can be damaged,
(4) expensive, but less than the
immunomagnetic beads.
[47, 68, 124, 141,
142]
Cytospin
(1) Easy,
(2) Allowing cytopathology, cytological
staining, ICH, FISH, and so forth,
(3) Allowing Microdissection followed by
(4) RNA, DNA extraction follow by RT-PCR
or PCR, respectively.
(1) Increasing the mortality of the
CTC. [65, 143–146]
Lysis Buﬀer
(Qiagen)
(1) Easy,
(2) the cells harvested by this method can be
reenriched or analysed by the methods
already described,
(3) low cost.
(1) Increasing the mortality of the
CTC,
(2) low sensitivity.
[147–149]
Speciﬁc
ImmunoMagnetic Beads
(MACS system, CellSearch)
(1) Speciﬁc,
(2) morphological analysis of CTC,
cytopathology, cytological staining, ICH,
FISH, and so forth,
(3) multiple labelling of antigens on CTC,
(4) direct quantiﬁcation of CTC.
(1) Subjective analyses for CTC
identiﬁcation,
(2) time-consuming screening of
tumor cells,
(3) needing speciﬁc marker(s) and
antibody available,
(4) expensive
[40, 150–152]
EPISPOT
(1) High sensitivity,
(2) detection of viable CTC,
(3) detection of secreted proteins
(1) Protein must be actively
secreted, shed, or released,
(2) no identiﬁcation and isolation
of secreting cell possible.
[40, 150–152]
FACS
(1) High sensitivity,
(2) technique for counting, examining, and
sorting microscopic particles (CTC)
suspended,
(3) simultaneous multiparametric analyses
of the physical and/or chemical
characteristics.
(1) Need the apparatus,
(2) high cost. [140, 153, 154]International Journal of Hepatology 7
Table 2: Continued.
Methods of enrichment Advantages Disadvantages References
FAST (1) High sensitivity,
(2) can detect rare events.
(1) Fluorescent dyeconjugated
antibodies,
(2) speciﬁcity depend on the
antibodies,
(3) very expensive.
[48, 89, 141, 155]
CTC-Chip (1) High sensitivity,
(2) detection of viable CTC,
(1) Detecting only cytokeratin ±
CTC,
(2) needing to control precisely
laminar ﬂow conditions,
(3) expensive.
[40, 156]
generated by placing layer after layer of gradient media such
as sucrose in a tube with the heaviest layer at the bottom and
thelightestatthetopineitheradiscontinuousorcontinuous
mode. The cell fraction to be separated is placed on top
of the layer and centrifuged. Density gradient separation
can be classiﬁed into two categories: (1) Rate-zonal (size)
separation. (2) Isopycnic (density) separation.
Rate-zonalseparationtakesadvantageofparticlesizeand
mass instead of particle density for sedimentation [157].
In isopycnic separation, a particle of a particular density
will sink during centrifugation until a position is reached
where the density of the surrounding solution is exactly
the same as the density of the particle. Once this quasi-
equilibrium is reached, the length of centrifugation does
not have any inﬂuence on the migration of the particle. A
common example for this method is separation of nucleic
acids in a CsCl gradient. A variety of gradient media can be
used for isopycnic separations [157–161].
In the context of the CTC enrichment by centrifugation
theisopycnicseparationisthemethodusuallyused.Thecells
that have a density higher than the density of the buﬀer will
stay in the bottom of the tube. If the density of the cells is
lower than the buﬀer, they will remain on the top of the
liquid, forming a ring. On the contrary, if the density of the
cells is the same than the buﬀer, the cells will form a ring in
themiddleofthetube.Awell-knownexampleofthemethod
is the commercial buﬀer Ficoll tube or Ficoll-Paque PLUS
(GE Healthcare Bioscience, Amersham Biosciences AB) or
Lymphoprep (Nicomed) to separate the red blood cells from
the other cells including CTC (Table 2).
OncoQuick (Greiner) method uses a speciﬁc buﬀer
able to isolate the CTC [47, 139, 140]. These methods
are usually fast but expensive and found in a context
of clinical laboratory used in routine diagnosis (Table 2).
Alternative and cheaper methods can be used by preparing
in the laboratory the gradient/density buﬀers. The same tube
can contain one, two or three gradient buﬀers to increase
the speciﬁcity of the separation between the diﬀerent cells
present in the blood [27, 47, 162, 163].
6.2. Lysis Buﬀers. The content of diﬀerent cells has diﬀerent
osmotic pressures. It is possible to expose the samples to
buﬀer(s) that can be hypo-or hyperosmotic to any cell
diﬀerent to the target cells. After the lysis step the mix
is centrifuged and the pellets will contain the CTC. Some
companies provide a kit with lysis buﬀers ready to use. After
lysis, the next step is the extraction of DNA or RNA (e.g.,
Red Lysis Buﬀer from Qiagen or Panomics) or the extracted
cells can be puriﬁed by immunomagnetic beads enrichment
[147–149]. However, methods using lysis buﬀer can induce
the death of a lot of cells including the CTC and it is not
appropriate if the sample contains few CTC leading to false
negative results.
6.3. Cytocentrifugation (Cytospin). The cytocentrifugation
was designed for hypocellular ﬂuids; it spins at lower speeds
and has more gradual acceleration and deceleration than
normal centrifuges. Some are able to deposit cells directly
onto a slide for examination. Cytocentrifugation could be
used in research purposes and is also widely used in the
routine surgical pathology practice. This method is fast and
aﬀordable [65, 144, 145, 164].
Methods to identify CTC can after be used (see below).
As it occurs with magnetic beads, cytospin increases mor-
tality of the target cells (Table 2). Because enrichment by
cytocentrifugation is a critical step, addition of 10% buﬀered
formaldehyde solution added to the blood sample can
preserve morphology of the cells and will certainly preserve
nucleic acids integrity [143], but the disadvantage of this
method is that formaldehyde kills the cells (Table 2). Liquid-
basedcytology(LBC)usingaﬁltrationprocessandcomputer
assisted thin layer deposition of cells has been developed
as a replacement for cytocentrifugation and/or smearing,
owingtoitsimprovedcellrecoverycapabilitiesandbettercell
preservation. In most published series, LBC allows a good
interobserver reproducibility [165–167].
There are several advantages to this system. One is that
it produces a thin layer of cells which is easier to evaluate
than a thick smear. The morphology of the cells is also
better. In addition, the entire cell sample is captured in the
ﬁxative vial which leads to a more representative smear being
prepared. One of the most important advantages of this
test is that the material that is left over after a smear has
been prepared can be used for adjunctive testing. A further
advantage is that the smears may be initially subjected to
image analysis. Computer software “reads” the smears and
registers the coordinates of the ﬁelds with what it regards as
the most abnormal cells. On review, the system directs the8 International Journal of Hepatology
cytotechnologists to these ﬁelds where they are evaluated.
Thiscancutdownontechnologists’screeningtime(Table 2).
There are also some disadvantages, which include
increased manpower needed to prepare the smears and the
dependence of smear preparation on the instrument. This
technique cannot be used directly from blood samples. The
red blood cells need to be eliminated (See Table 2)a n da f t e r
the sample can be processed by this technique (Table 2).
However, optimization of cell capture and ﬁxation can be
achieved by methods other than Cytyc Thinprep LBC, par-
ticularly while using meticulous modern cytocentrifugation
methods in the study of hypocellular ﬂuids [166, 167]. In
their study, Piaton et al. conclude that Cytyc Thinprep LBC
and modern cytocentrifugation techniques are appropriate
methods for cytology-based molecular studies. From an
economical point of view (standard cytocentrifugation are
around $ 538 compared to Cytyc ThinprepH $ 1,278),
and taking into account the value of a meticulous tech-
nique, cytocentrifugation with disposable sample chambers
remainsthequalitystandardforcurrenttreatmentofurinary
samples for example [166].
6.4.Filters. Anonspeciﬁcmethodofenrichmentusingﬁlters
can captured the cells with a certain size. The cells captured
on the ﬁlter can after be transferred and analyzed on a
slide. In this case the samples can come from blood or
body ﬂuids (urines, cerebrospinal ﬂuid, and ascites). We will
describe tow kinds of methods using this technology and
usually used to isolate CTC (Table 2): the Isolation by Size
of Epithelial Tumor Cells (ISET) method and the Micro-
Electro-Mechanical System (MEMS).
6.4.1. The Isolation by Size of Epithelial Tumor Cells.
(ISET) method (Metagenex, Paris, France, http://www
.metagenex.fr/)separatescellsbysizewithaﬁlter.Cellslarger
than 10μm, including tumor cells from carcinomas, are
enriched from leukocytes (erythrocytes are lysed, see above)
onaﬁlter.EnrichedcellsarestainedontheﬁlterandCTCare
precisely counted after cytopathological evaluation. The cells
on the ﬁlter can be also studied by immunolabelling, FISH,
TUNEL, and molecular analysis. Molecular analysis can be
performed speciﬁcally to CTC after laser microdissection.
The ﬁlter can be also mounted between slide and coverslip
for routine microscope observation and storage. Although
promising, this method is expensive, time consuming, and
the ﬁlters are not easily available [47, 68, 141]. Cells
should be better characterized using morphological methods
that allow both detection and characterization. A second
potential main advantage is that CTC could be compared
to the primary tumor in order to better understand the
mechanism of metastatic process. However, this approach
hasbeenrarelyperformedandneitherﬁrmrecommendation
nor conclusion could be drawn. The technique also avoids
damaging the tumor cell which can be diagnosed using a
simple pathologist analysis. However, the pathologist should
get use to this technique to avoid a misinterpretation with
otherstypesofcells.TheuseofISETtechnologytodetectand
characterize CTC in HCC has been reported in one study.
Vona et al. reported that microemboli and isolated CTC
couldbedetectedinHCCpatient[142].PresenceofCTCwas
associated with a shorter survival. This work also showed the
feasibility of molecular studies of individual circulating cells.
Indeed, β-Catenin mutations were searched in samples of 60
single microdissected CTC. β-Catenin mutations were found
in only 3 CTC that highlighted the weak impact of these
mutations in the initial step of tumor cell invasion. Further
studies are needed.
6.4.2. The Micro-Electro-Mechanical System (MEMS). It is
a parylene membrane microﬁlter device for single stage
capture and electrolysis of circulating tumor cells in human
blood and the potential of this device to allow genomic
analysis. After the CTC, are captured in the ﬁlter, electrical
lysis of cells on membrane ﬁlter is applied and the DNA
as well as RNA can be extracted and analyzed by PCR
or RT-PCR, respectively. CTC enrichment is performed by
eithergradientcentrifugationofCTCbasedontheirbuoyant
density or magnetic separation of epithelial CTC, both of
which are laborious procedures with variable eﬃciency, and
CTC identiﬁcation is typically done by trained pathologists
through visual observation of stained cytokeratin-positive
epithelial CTC. These processes may take hours, if not
days.The Micro-Electro-MechanicalSystem(MEMS-)based
makes the process simpler faster and better to separate CTC
(∼90% recovery) from blood cells. Since enrichment will
inevitably be accompanied by loss of CTC, irrespective of the
exact method, some essays are performed directly in whole
blood [89]. But the disadvantages of this technique are that
morphology of the cells is lost, besides markers also and the
capacity to count exactly the number of CTC (Table 2).
7. The SpeciﬁcEnrichmentTechniques
T h es p e c i ﬁ ce n r i c h m e n tt e c h n i q u e sc a nu s es p e c i ﬁ c a l l y
protein tumoral markers expressed by the CTC. These
methods use antibodies against the protein tumoral markers
coupled to steel beads, by applying a magnetic ﬁeld the cells
expressing the marker can be captured. Several immune-
magnetic methods (MACS system, Deanabeads Invitrogen,
macroiron beads, ferroﬂuid(colloidal iron-) based systems)
to enrich the sample have been used successfully [168].
Another approach to enrich the sample is to use the
properties of CTC to grow-up in a speciﬁc culture cell
medium. A method (EPISPOT) that combines the capacity
of CTC to secret speciﬁc markers and grow-up in speciﬁc cell
medium was developed (see Table 2).
7.1. Magnetic Separation. To use immune-magnetic detec-
tion system the ﬁrst step is to deplete the whole blood
of the red cells (by lysis buﬀers or density gradient) to
obtain the PBMC. After, the magnetic particles coated
and surrounded by a speciﬁc antibody are added to the
PBMC supposing containing the CTC. Labeled cells are then
collected by applying a magnetic force while nonlabeled cells
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ofmagneticbeadstocatchspeciﬁcallyCTCiscalled“positive
selection” [40, 47, 49].
Since a large number of leukocytes (potential source
of false negative CTC) still remain trapped with the cells,
some methods include a “negative selection” of leukocytes
(with anti-CD 45 beads for example) followed with a
“positive selection” with antibodies speciﬁc to epithelial cells
(EpCAM, CK) [47, 169, 170]. The problem of this procedure
is that gets ride the majority of leukocytes but still hold in
nonmalignant epithelial cells and loses tumor cells which
whish do not express epithelial antigens and/or are lysed
during the ﬁrst step [47, 171].
The methods using antibodies like immune-magnetic
methods (MACS system, Deanabeads Invitrogen, macroiron
beads,ferroﬂuid(colloidaliron-)basedsystems)toenrichthe
sample will induce false-positive extraction [168]. For exam-
ple, antibodies against cytokeratin (CK) or other epithelial-
speciﬁc antigens have been reported to bind both speciﬁcally
and nonspeciﬁcally to macrophages, plasma cells and nucle-
ated hematopoietic cells precursors. The nonspeciﬁc binding
of theantibodies involves Fcreceptor-bearing leukocytes and
monocytes or illegitimate expression of epithelial antigens
in normal hematopoietic cells. Some of these positive cells
are morphologically diﬃcult to distinguish from CTC.
Variable numbers of epithelial cells have been found in
peripheral blood of subject without malignancy in some
physiopathological conditions like benign epithelial prolif-
erative diseases, inﬂammation, surgeries, and tissue trauma
[47, 65, 169, 172–174]. Moreover, epithelial CTC may lose
epithelial markers during dissemination through the process
called epithelial-to-mesenchymal transition (EMT). Since
the epithelial markers that get lost during EMT may include
markers used for CTC measurement, underestimation of
the actual CTC number may occur, inducing de facto false-
negative results [46, 47, 49, 175, 176]. In the case that the
method induce false positive, the problem can be diminished
avoided using a second marker or a full panel of markers
and techniques (see below) to characterize the CTC, like
RT-PCR, immunocytochemistry or immuneﬂuorescence,
morphology by optical microscopy [37, 47, 49]. In another
hand, in the case of the false negative results the doubt
persist, and only strict followup of the patient by repeating
the detection of the CTC can potentially eliminate this
doubt. No available antibodies are 100% tumor or tissue
speciﬁc [13, 47, 172]. To isolate CTC a method using
a ligand biotinylated was used. Biotinylated asialofetuin,
al i g a n do fa s i a l o g l y c o p r o t e i nr e c e p t o r ,w a se x p e r i m e n t e d
and followed by magnetic separation or density gradient
(Ficoll-Paque PLUS; GE Healthcare). The cells were iden-
tiﬁed by microscopy, FISH, immunoﬂuorescence staining,
ﬂux cytometry, and RT-PCR. This technique shows 81%
speciﬁcity and 20 cells/5mL for the sensitivity [177]. This
promising approach has to be conﬁrmed in a larger cohort
of patients and still depends on the receptors expressed at the
surface of the CTC.
7.2. Culture of CTC. After isolation of the CTC by the
diﬀerentmethodsdescribedabove,toincreasethenumberof
CTC, the primary tumor cells can be cultured in the speciﬁc
culture medium [169]. The good conditions of culture
growth and specially the culture medium leading the growth
of the CTC, but not the other epithelial or nonepithelial
cells, has to be determined through an experiment. Some
companies propose commercial kits. For example, The
Cancer Cell Isolation Kit from Panomics includes lysis buﬀer
to increase the number of CTC. One of the main problems
is that cultured cells can lose their original markers and
derive. Mimicry of tumoral microenvironment in vitro is
particularly diﬃcult because for most tumors it is largely
unknown. Another problem is that the samples containing
the CTC are usually contaminated by stromal cells like
ﬁbroblasts, which create competition in the Petri dish. After
few days, only the ﬁbroblasts are present in the ﬂask.
7.3. Epithelial ImmunoSPOT (EPISPOT). A technique that
allows the detection of only viable cells after a CD45+
cell depletion was introduced for CTC analysis from bone
marrow aspirates and blood samples [40, 43, 151]. This tech-
nique was designated EPISPOT (epithelial ImmunoSPOT).
It is a protein-secreting proﬁling based on the secretion
or active release of speciﬁc marker proteins using an
adaptation of the enzyme-linked immunospot technology.
As immunospots are the protein ﬁngerprint left only by
the viable releasing epithelial cells, a cell culture is needed
to accumulate a suﬃcient amount of the released marker
proteins (Table 2). The dying cells do not secrete adequate
amounts of protein and are not detected [40, 150–152].
This assay can also provide important information on the
proﬁle of secreted proteins potentially relevant for metastasis
formation.However,thistechniquehasstilltobevalidatedin
large-scale clinical studies on cancer patients [40, 151]. After
the enrichment and isolation of the CTC, the next step is to
identify, characterize, and ﬁnally enumerate them. The CTC
can be identiﬁed by indirect or direct methods. But these
important steps need tumor markers speciﬁc to the CTC
seeked.
8. ExperimentalModels
8.1. HCC Mouse Models. Over decades, diﬀerent HCC
mouse models have been developed.
Chemically induced HCC-models are diverse and not
always reproducible. The chemicals usually used are diethyl-
nitrosamine (DEN), peroxisome proliferators, aﬂatoxine,
carbon tetrachloride (CCl4), choline deﬁcient diet or thi-
acetamide [178, 179] .T r a n s g e n i cm o u s em o d e l sw e r ea l s o
developed, for example, mice that contained HBV or HCV
viruses or expressed speciﬁcally oncogenes (c-myc, c-myc
+ E2F1) or growth factors (TGF-α,T G F - α + c-myc, EGF,
FGF19, GMNT, PDGF, α1-antitrypsin) [178]. Circulating
tumor cells were not looked for in any of these animal
models. One reason is the huge diﬀerences between models
and the presence of speciﬁc markers for each situation.
In order to solve these problems, researchers developed
ectopic implantation that is fast and easy to perform.
However,thereisstillmanydiﬀerencesbetweenthecelllines,10 International Journal of Hepatology
no direct interaction with the liver tissues and diﬃculty to
export to humans [178].
8.2. Orthotopic Implantation. Orthotopic implantation is a
more suitable model because the cells are directly implanted
in the liver tissue. Nevertheless, the procedure is challenging.
There are big diﬀerences between cell lines and the choice
of the markers is still limited [178]. Mechanisms leading
to tumoral cells spreading are ill known. Currently, there
are few models of orthotopic implantation of human
tumoral cells [180, 181]. An experimental model of human
orthotopic HCC transplantation in NOD/SCID (nonobese
diabetic/several compromise immunodeﬁcient) mice allows
to generate and to modulate CTC [180, 181]. In this mouse
model, tumoral spreading is an early event during tumoral
development and the number of CTC is directly correlated
to the tumor size.
When injected under the liver capsule, a primary tumor
develops and continuously yields circulating tumor cells.
In addition, the CTC could be modulated after tumor
removal. Liver tumor removal led to a very low level of
tumoral cells in blood 30 days later. After complete tumor
removal, the number of CTC signiﬁcantly decreases but still
remains detectable even at a low level. The FACS was used
to detect CTC (detection of human HLA marker in mouse
bloodstream).TherealityofCTCwasthendemonstrated.An
importantﬁndingisthatthebonemarrowcouldbeearlyand
permanently colonized by CTC [181].
8.3. Small Imaging Animal Models. With the recent develop-
ment of the small imaging apparatus (example: IVIS Lumina
II XR Imaging System, positron emission tomography) to
study development and the progression of diseases in the
live animals like rheumatism, a new area to study CTC in
live animals is open. This technique was applied to study the
CTC in ectopic or orthotopic HCC cell lines implantation.
As we discuss below, the lack of speciﬁc HCC markers
makes CTC studies very challenging. The idea is to bind
luminescence tag (luciferase, yellow ﬂuorescence, or red
ﬂuorescence proteins) in the hepatoma cell lines injected
in the liver that be detected by bioluminescence machine.
For example, thymidine kinase-luciferase was placing under
the transcriptional control of endogenous AFP promoter to
develop a transgenic mouse model that injected with DEN
will develop HCC [182]. The development of the HCC was
followed in the live animal by bioluminescence and PET
analyses. The inconvenient of this method is that the HCC
model has to express AFP. To avoid this problem hepatoma
celllineswhereengineeredwithluciferase(HCC-LM3)[183]
or red luminescence protein [184]. This approach to study
CTC in the context of HCC is very promising, but the major
problem is the sensitivity of the bioluminescence machine.
This approach has not yet studied in the context of CTC in
the blood or in organs other than liver.
In vivo ﬂow cytometry method to detect CTC from HCC
has been developed. This method combined the ﬂow cytom-
etry technology that can detect speciﬁc ﬂuorochromes based
on their wavelengths, the speciﬁcity of these ﬂuorochromes
attached to an antibody that detects the CTC or ﬂuorescently
labelled cells as described in Li et al. paper [185]. Brieﬂy,
ﬂuorescence signal from a given circulating cell population
is recorded as the cells pass through the slit of light. Confocal
detection of the excited ﬂuorescence enables continuous
monitoring of labeled cells in the upper layers of scattering
tissue, such as the skin of a mouse ear. Based on algorithm
anddataanalysisthecomputerisabletoestimatethenumber
of CTC in the blood stream. This method is still used in
animal models to detect CTC from HCC but as promising
future to detect CTC in human patients.
9. Conclusion
There are two major problems to detect circulating hepa-
tocarcinoma cells in the human blood. The ﬁrst problem
is the low number of speciﬁc markers known. The second
problem is that few cells are present in the bloodstream. To
overcometheseproblems,fewyearsagonewapproacheshave
been developed such as the techniques to study membrane
proteins by mass spectrometry and the development of
ﬂuorescent hepatoma cells.
Nowadays, these procedures are not suitable in clinical
practice. However, it is undeniable that early detection of
tumors and metastasis is urgently needed in medicine and
these new exciting techniques and ﬁndings are changing our
point of view of carcinogenesis very fast. In the future, CTC
detection will certainly be an important diagnostic tool in
cancer patients, providing a new and accurate assessment of
lesion staging.
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